Brief: Durect Corporation Announces Topline Results From Phase 2B AHFIRM Trial Of Larsucosterol In Alcohol-Associated Hepatitis With Promising Effect On Mortality

DURECT

07/11/2023 21:47

Nov 7 (Reuters) - DURECT Corp  DRRX.O :
    * DURECT CORPORATION ANNOUNCES TOPLINE RESULTS FROM PHASE 2B
AHFIRM TRIAL OF LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
WITH PROMISING EFFECT ON MORTALITY
    * DURECT CORP - COMPELLING EFFICACY SIGNAL IN FAVOR OF
LARSUCOSTEROL IN KEY SECONDARY ENDPOINT OF MORTALITY AT 90 DAYS
    * DURECT CORP - CLINICALLY RELEVANT REDUCTION IN 90-DAY
MORTALITY
OF 41% FOR 30 MG DOSE AND 35% FOR 90 MG DOSE COMPARED WITH
STANDARD OF CARE
    * DURECT CORP - NUMERICAL IMPROVEMENT IN PRIMARY ENDPOINT OF
MORTALITY OR TRANSPLANT AT 90 DAYS DID NOT ACHIEVE STATISTICAL
SIGNIFICANCE
    * DURECT CORP - NUMERICAL IMPROVEMENT IN PRIMARY ENDPOINT OF
MORTALITY OR TRANSPLANT AT 90 DAYS DID NOT ACHIEVE STATISTICAL
SIGNIFICANCE
    * DURECT CORP - LARSUCOSTEROL WAS WELL-TOLERATED AND BOTH 30
MG
AND 90 MG DOSE GROUPS HAD NUMERICALLY FEWER ADVERSE EVENTS THAN
SOC

Source text for Eikon:  ID:nPn9BZtfJa 
Further company coverage:  DRRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))